🇺🇸 FDA
Patent

US 10040826

Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens

granted A61KA61K2039/6075A61K38/00

Quick answer

US patent 10040826 (Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens) held by The United States of America as represented by the Secretary of the Army expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Army
Grant date
Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
67
CPC classes
A61K, A61K2039/6075, A61K38/00, A61K39/12, A61K39/21